MicroRNA-145 inhibits growth of laryngeal squamous cell carcinoma by targeting the PI3K/Akt signaling pathway

References

• Chu EA, Kim YJ. Laryngeal cancer: diagnosis and preoperative work-up. Otolaryngol Clin North Am. 2008;41(4):673–695. doi:10.1016/j.otc.2008.01.01618570953
   PubMed Web of Science ®Google Scholar
• Babashah S, Soleimani M. The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. Eur J Cancer. 2011;47(8):1127–1137. doi:10.1016/j.ejca.2011.02.00821402473
   PubMed Web of Science ®Google Scholar
• Lu Y, Chopp M, Zheng X, Katakowski M, Buller B, Jiang F. MiR-145 reduces ADAM17 expression and inhibits in vitro migration and invasion of glioma cells. Oncol Rep. 2013;29(1):67–72. doi:10.3892/or.2012.208423076445
   PubMed Web of Science ®Google Scholar
• Sachdeva M, Mo YY. miR-145-mediated suppression of cell growth, invasion and metastasis. Am J Trans Res. 2010;2(2):170–180.
   PubMed Web of Science ®Google Scholar
• Lin Y, Ge X, Wen Y, et al. MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells. Oncotarget. 2016;7(43):70857–70868. doi:10.18632/oncotarget.1226827765914
   PubMed Web of Science ®Google Scholar
• Arndt GM, Dossey L, Cullen LM, et al. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer. 2009;9:374. doi:10.1186/1471-2407-9-37419843336
   PubMed Web of Science ®Google Scholar
• Chiyomaru T, Enokida H, Tatarano S, et al. miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer. 2010;102(5):883–891. doi:10.1038/sj.bjc.660557020160723
   PubMed Web of Science ®Google Scholar
• Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007;67(18):8699–8707. doi:10.1158/0008-5472.CAN-07-193617875710
   PubMed Web of Science ®Google Scholar
• Kano M, Seki N, Kikkawa N, et al. miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer. 2010;127(12):2804–2814. doi:10.1002/ijc.2528421351259
   PubMed Web of Science ®Google Scholar
• Zaman MS, Chen Y, Deng G, et al. The functional significance of microRNA-145 in prostate cancer. Br J Cancer. 2010;103(2):256–264. doi:10.1038/sj.bjc.660574220588276
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441(7092):424–430. doi:10.1038/nature0486916724053
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Lippman SM. Advances in the biology of lung cancer chemoprevention. J Clin Oncol. 2005;23(14):3186–3197. doi:10.1200/JCO.2005.14.20915886305
   PubMed Web of Science ®Google Scholar
• Dai R, Chen R, Li H. Cross-talk between PI3K/Akt and MEK/ERK pathways mediates endoplasmic reticulum stress-induced cell cycle progression and cell death in human hepatocellular carcinoma cells. Int J Oncol. 2009;34(6):1749–1757.19424594
   PubMed Web of Science ®Google Scholar
• Yang M, Wang H, Zhou M, et al. The natural compound sulforaphene, as a novel anticancer reagent, targeting PI3K-AKT signaling pathway in lung cancer. Oncotarget. 2016;7(47):76656–76666. doi:10.18632/oncotarget.1230727765931
   PubMedGoogle Scholar
• Liu S, Duan W. Long noncoding RNA LINC00339 promotes laryngeal squamous cell carcinoma cell proliferation and invasion via sponging miR-145. J Cell Biochem. 2018 Epub ahead of print. doi:10.1002/jcb.28110.
   Google Scholar
• Gao W, Zhang C, Li W, et al. Promoter methylation-regulated miR-145-5p inhibits laryngeal squamous cell carcinoma progression by targeting FSCN1. Mol Ther. 2019;27(2):365–379. Epub 2018 Sep 27. doi:10.1016/j.ymthe.2018.09.01830341010
   PubMed Web of Science ®Google Scholar
• Zhao X, Zhang W, Ji W. MYO5A inhibition by miR-145 acts as a predictive marker of occult neck lymph node metastasis in human laryngeal squamous cell carcinoma. Onco Targets Ther. 2018;11:3619–3635. eCollection 2018. doi:10.2147/OTT.S16459729950866
   PubMed Web of Science ®Google Scholar
• Zhu X, Zhu R. Curcumin suppresses the progression of laryngeal squamous cell carcinoma through the upregulation of miR-145 and inhibition of the PI3K/Akt/mTOR pathway. Onco Targets Ther. 2018;11:3521–3531. eCollection 2018. doi:10.2147/OTT.S15923629950857
   PubMed Web of Science ®Google Scholar
• Zhu Y, Yan L, Zhu W, Song X, Yang G, Wang S. MMP2/3 promote the growth and migration of laryngeal squamous cell carcinoma via PI3K/Akt-NF-κB-mediated epithelial-mesenchymal transformation. J Cell Physiol. 2019 Epub ahead of print. doi:10.1002/jcp.28242.
   Google Scholar
• Ni HS, Hu SQ, Chen X, Liu YF, Ni TT, Cheng L. Tra2β silencing suppresses cell proliferation in laryngeal squamous cell carcinoma via inhibiting PI3K/AKT signaling. Laryngoscope. 2018 Epub ahead of print. doi:10.1002/lary.27716.
   Web of Science ®Google Scholar
• Jiang T, Zhou ML, Fan J. Inhibition of GLUT-1 expression and the PI3K/Akt pathway to enhance the chemosensitivity of laryngeal carcinoma cells in vitro. Onco Targets Ther. 2018;11:7865–7872. eCollection 2018. doi:10.2147/OTT.S17681830464533
   PubMed Web of Science ®Google Scholar
• Bartels CL, Tsongalis GJ. MicroRNAs: novel biomarkers for human cancer. Ann Biol Clin (Paris). 2010;68(3):263–272. doi:10.1684/abc.2010.042920478768
   PubMedGoogle Scholar
• Dip N, Reis ST, Srougi M, Dall’Oglio MF, Leite KR. Expression profile of microRNA-145 in urothelial bladder cancer. Int Braz J Urol. 2013;39(1):95–101; discussion 102. doi:10.1590/S1677-5538.IBJU.2013.01.12
   PubMed Web of Science ®Google Scholar
• Du L, Pertsemlidis A. microRNAs and lung cancer: tumors and 22-mers. Cancer Metastasis Rev. 2010;29(1):109–122. doi:10.1007/s10555-010-9204-920130964
   PubMed Web of Science ®Google Scholar
• Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med. 2009;60:167–179. doi:10.1146/annurev.med.59.053006.10470719630570
   PubMed Web of Science ®Google Scholar
• Huang L, Lin JX, Yu YH, Zhang MY, Wang HY, Zheng M. Downregulation of six microRNAs is associated with advanced stage, lymph node metastasis and poor prognosis in small cell carcinoma of the cervix. PloS One. 2012;7(3):e33762. doi:10.1371/journal.pone.003376222438992
   PubMed Web of Science ®Google Scholar
• Lee SE, Bairstow SF, Werling JO, et al. Paclitaxel nanosuspensions for targeted chemotherapy - nanosuspension preparation, characterization, and use. Pharm Dev Technol. 2014;19(4):438–453. doi:10.3109/10837450.2013.78991123617261
   PubMed Web of Science ®Google Scholar
• Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs. 1999;17(4):343–359.10759402
   PubMed Web of Science ®Google Scholar
• Hoffman RM. Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. Nat Rev Cancer. 2015;15(8):451–452. doi:10.1038/nrc397226422835
   PubMed Web of Science ®Google Scholar
• Hoffman RM. Patient-Derived Mouse Models of Cancer. Berlin: Springer Intl; 2017.
   Google Scholar
• Li C, Xu N, Li YQ, Wang Y, Zhu ZT. Inhibition of SW620 human colon cancer cells by upregulating miRNA-145. World J Gastroenterol. 2016;22(9):2771–2778. doi:10.3748/wjg.v22.i9.277126973415
   PubMed Web of Science ®Google Scholar
• Ibrahim AF, Weirauch U, Thomas M, Grunweller A, Hartmann RK, Aigner A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res. 2011;71(15):5214–5224. doi:10.1158/0008-5472.CAN-10-464521690566
   PubMed Web of Science ®Google Scholar
• Zhong M, Ma X, Sun C, Chen L. MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer. Chem Biol Interact. 2010;184(3):431–438. doi:10.1016/j.cbi.2010.01.02520097187
   PubMed Web of Science ®Google Scholar
• Zhu X, Li Y, Xie C, et al. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. Int J Cancer. 2014;135(6):1286–1296. doi:10.1002/ijc.2877424510775
   PubMed Web of Science ®Google Scholar
• Boufraqech M, Zhang L, Jain M, et al. miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3. Endocr Relat Cancer. 2014;21(4):517–531. doi:10.1530/ERC-14-007724781864
   PubMed Web of Science ®Google Scholar
• Wang Y, Hu C, Cheng J, et al. MicroRNA-145 suppresses hepatocellular carcinoma by targeting IRS1 and its downstream Akt signaling. Biochem Biophys Res Commun. 2014;446(4):1255–1260. doi:10.1016/j.bbrc.2014.03.10724690171
   PubMed Web of Science ®Google Scholar
• Liu Y, Wu C, Wang Y, et al. MicroRNA-145 inhibits cell proliferation by directly targeting ADAM17 in hepatocellular carcinoma. Oncol Rep. 2014;32(5):1923–1930. doi:10.3892/or.2014.342425174729
   PubMed Web of Science ®Google Scholar
• Fuse M, Nohata N, Kojima S, et al. Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol. 2011;38(4):1093–1101. doi:10.3892/ijo.2011.91921258769
   PubMed Web of Science ®Google Scholar
• Wang S, Bian C, Yang Z, et al. miR-145 inhibits breast cancer cell growth through RTKN. Int J Oncol. 2009;34(5):1461–1466.19360360
   PubMed Web of Science ®Google Scholar
• Zhang J, Guo H, Qian G, et al. MiR-145, a new regulator of the DNA fragmentation factor-45 (DFF45)-mediated apoptotic network. Mol Cancer. 2010;9:211. doi:10.1186/1476-4598-9-25420687965
   PubMed Web of Science ®Google Scholar
• Derouet MF, Liu G, Darling GE. MiR-145 expression accelerates esophageal adenocarcinoma progression by enhancing cell invasion and anoikis resistance. PloS One. 2014;9(12):e115589. doi:10.1371/journal.pone.011558925551563
   PubMed Web of Science ®Google Scholar
• Koo S, Martin G, Toussaint LG. MicroRNA-145 promotes the phenotype of human glioblastoma cells selected for invasion. Anticancer Res. 2015;35(6):3209–3215.26026080
   PubMed Web of Science ®Google Scholar
• Lei P, Xie J, Wang L, Yang X, Dai Z, Hu Y. microRNA-145 inhibits osteosarcoma cell proliferation and invasion by targeting ROCK1. Mol Med Rep. 2014;10(1):155–160. doi:10.3892/mmr.2014.219524789502
   PubMed Web of Science ®Google Scholar
• Ostenfeld MS, Bramsen JB, Lamy P, et al. miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene. 2010;29(7):1073–1084. doi:10.1038/onc.2009.39519915607
   PubMed Web of Science ®Google Scholar
• Sachdeva M, Zhu S, Wu F, et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A. 2009;106(9):3207–3212. doi:10.1073/pnas.080804210619202062
   PubMed Web of Science ®Google Scholar
• Kent OA, Chivukula RR, Mullendore M, et al. Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev. 2010;24(24):2754–2759. doi:10.1101/gad.195061021159816
   PubMed Web of Science ®Google Scholar
• Spizzo R, Nicoloso MS, Lupini L, et al. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ. 2010;17(2):246–254. doi:10.1038/cdd.2009.11719730444
   PubMed Web of Science ®Google Scholar
• Sachdeva M, Mo YY. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res. 2010;70(1):378–387. doi:10.1158/0008-5472.CAN-09-202119996288
   PubMed Web of Science ®Google Scholar
• Gotte M, Mohr C, Koo CY, et al. miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene. 2010;29(50):6569–6580. doi:10.1038/onc.2010.38620818426
   PubMed Web of Science ®Google Scholar
• Cordes KR, Sheehy NT, White MP, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature. 2009;460(7256):705–710. doi:10.1038/nature0819519578358
   PubMed Web of Science ®Google Scholar
• Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell. 2009;137(4):647–658. doi:10.1016/j.cell.2009.02.03819409607
   PubMed Web of Science ®Google Scholar
• Gregersen LH, Jacobsen AB, Frankel LB, Wen J, Krogh A, Lund AH. MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One. 2010;5(1):e8836. doi:10.1371/journal.pone.000883620098684
   PubMed Web of Science ®Google Scholar
• La Rocca G, Badin M, Shi B, et al. Mechanism of growth inhibition by MicroRNA 145: the role of the IGF-I receptor signaling pathway. J Cell Physiol. 2009;220(2):485–491. doi:10.1002/jcp.2179619391107
   PubMed Web of Science ®Google Scholar
• Zhang J, Guo H, Zhang H, et al. Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene. Cancer. 2011;117(1):86–95. doi:10.1002/cncr.2552220737575
   PubMed Web of Science ®Google Scholar
• Zhang XF, Zhang XQ, Chang ZX, Wu CC, Guo H. microRNA145 modulates migration and invasion of bladder cancer cells by targeting Ncadherin. Mol Med Rep. 2018;17(6):8450–8456. doi:10.3892/mmr.2018.891029693148
   PubMed Web of Science ®Google Scholar
• Mo D, Yang D, Xiao X, Sun R, Huang L, Xu J. MiRNA-145 suppresses lung adenocarcinoma cell invasion and migration by targeting N-cadherin. Biotechnol Lett. 2017;39(5):701–710. doi:10.1007/s10529-017-2290-928120164
   PubMed Web of Science ®Google Scholar
• Ye D, Shen Z, Zhou S. Function of microRNA-145 and mechanisms underlying its role in malignant tumor diagnosis and treatment. Cancer Manage Res. 2019;11:969–979. doi:10.2147/CMAR.S191696
   PubMed Web of Science ®Google Scholar